Heart failure after myocardial infarction: A neglected problem?

British Journal of Cardiology

Volumn 12, Issue 3, 2005, Pages 205-208

  Cowie, Martin R ^a   Lacey, Larry ^b   Tabberer, Maggie ^c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Lacey Solutions Ltd   (Ireland)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Acute myocardial infarction; Epidemiology; Heart failure; Left ventricular systolic dysfunction; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VALSARTAN;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; CLINICAL PATHWAY; CLINICAL TRIAL; COMMUNITY CARE; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; FIBRINOLYSIS; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HIGH RISK POPULATION; HOSPITAL SERVICE; HUMAN; INCIDENCE; MORTALITY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; UNITED KINGDOM;

EID: 21044445010     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. National Collaborating Centre for Chronic Conditions. Chronic heart failure: national clinical quideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians of London, July 2003. Available at www.rcplondon.ac.uk
2. Department of Health. National Service Framework for Coronary Heart Disease. London: Department of Health, 2000. Also available at www.doh.gov.uk/nsf/coronary.htm
3. Cleland JG, McGowan J. Heart failure due to schaemic heart disease: epidemiology, pathophysiology and progression. J Cardiovasc Pharmacol 1999;33(suppl 3):S17-S29.
4. Bleske BE. Evolution and pathophysiology of chronic systolic heart failure. Pharmacotherapy 2000;20:349S-358S.
5. Davies MK, Hobbs FDR, Davis RC et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001;358: 439-44.
6. McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJV. Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet 1997;350:829-33.
7. Cowie MR, Wood DA, Coats AJS et al. Incidence and aetiology of heart failure. A population-based study. Eur Heart J 1999;20:421-8.
8. Cowie MR, Wood DA, Coats AJ et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000;83:505-10.
9. Cleland JG, Swedberg K, Follath F and the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24:442-63.
10. Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet 2003;362:147-58.
11. Davis RC, Hobbs DR, Kenkre E et al. Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. BMJ 2002; 325:1156-60.
12. British Heart Foundation. Coronary Heart Disease Statistics Heart Failure Supplement. London: British Heart Foundation, 2002. Available at www.bhf.org.uk
13. Fox KF, Cowie MR, Wood DA et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001;22:228-36.
14. Spencer FA, Meyer TE, Gore JM et al. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction. Circulation 2002;105:2605-10.
15. Vaur L, Danchin N, Genes N et al. Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase. Am Heart J 1999; 137:49-58.
16. British Heart Foundation. Coronary Heart Disease Statistics Database. London: British Heart Foundation, 2003. Available at www.bhf.org,uk
17. Hellermann JF, Jacobsen SJ, Gersh BJ et al. Heart failure after myocardial infarction: a review. Am J Med 2002; 113:324-30.
18. Ali AS, Rybicki BA, Alam M et al. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J 1999;138: 1133-9.
19. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-12.
20. Pfeffer MA, McMurray JJ, Velazquez EJ et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-906.
21. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
22. Pitt B, Remme W, Zannad F et al., for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
23. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:249-54.
24. Arnold JM, Yusuf S, Young J et al. and the HOPE Investigators. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107:1284-90.
25. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
26. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ 2003;326:196.